Last reviewed · How we verify
TCbHP VS ddEC-THP
TCbHP is a histone deacetylase inhibitor, which works by blocking the activity of histone deacetylases to modify gene expression.
TCbHP is a histone deacetylase inhibitor, which works by blocking the activity of histone deacetylases to modify gene expression. Used for Metastatic non-small cell lung cancer, Acute myeloid leukemia.
At a glance
| Generic name | TCbHP VS ddEC-THP |
|---|---|
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Histone deacetylases are enzymes that remove acetyl groups from histones, leading to chromatin compaction and reduced gene transcription. By inhibiting these enzymes, TCbHP increases the acetylation of histones, resulting in increased gene transcription and potentially leading to the death of cancer cells.
Approved indications
- Metastatic non-small cell lung cancer
- Acute myeloid leukemia
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |